SANTA CLARA, CA, Ancora Heart, a company developing a novel therapy to address heart failure, has closed an $80 million equity financing. Sands Capital, Sio Capital and an undisclosed strategic investor joined all existing investors in this financing.

Ancora Heart is a medical device company dedicated to providing new treatment options for people with heart failure (HF). The company's proprietary AccuCinch Ventricular Restoration System is the only completely transcatheter device designed to restore the structure and function of the enlarged left ventricle of the heart.